Inotuzumab

Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959) . Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4].

Product Specifications

CAS Number

[1660159-36-3]

Product Name Alternative

Humanized Anti-CD22 Recombinant Antibody

UNSPSC

12352203

Target

ADC Antibody; Apoptosis; CD22

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/inotuzumab.html

Purity

96.81

Solubility

10 mM in DMSO

Smiles

[Inotuzumab]

Molecular Weight

(146.48 kDa)

References & Citations

[4]Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18 (5) :1101-1116.|[1]Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9.|[2]Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3 (1) :96-104.|[3]Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137 (19) :2657-2661.